Rukobia — Competitive Intelligence Brief

Rukobia (FOSTEMSAVIR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed Potassium voltage-gated channel subfamily H member 2 Immunology Small molecule

Target snapshot

Rukobia (FOSTEMSAVIR) — GSK. Rukobia works by blocking the potassium voltage-gated channel subfamily H member 2, which is involved in the replication of the human immunodeficiency virus 1.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rukobia TARGET	FOSTEMSAVIR	GSK	marketed		Potassium voltage-gated channel subfamily H member 2	2020-01-01
Daklinza	DACLATASVIR	Bristol-Myers Squibb	marketed	Hepatitis C Virus NS5A Inhibitor	Potassium voltage-gated channel subfamily H member 2	2015-01-01
Sirturo	bedaquiline	Janssen Therap	marketed	Diarylquinoline Antimycobacterial	Potassium voltage-gated channel subfamily H member 2	2012-01-01
Invega Sustenna	PALIPERIDONE PALMITATE	Johnson & Johnson	marketed	Atypical Antipsychotic	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Coartem	LUMEFANTRINE	Novartis	marketed	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Ketek	TELITHROMYCIN	Sanofi	marketed	Ketolide Antibacterial	Potassium voltage-gated channel subfamily H member 2	2004-01-01
Trisenox	ARSENIC TRIOXIDE	Cephalon	marketed	High Risk QT Prolonging Agents	Potassium voltage-gated channel subfamily H member 2	2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.